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The concept of epithelial-mesenchymal transition (EMT), a process where cells change their epithelial towards a
mesenchymal phenotype, has gained overwhelming attention especially in the cancer research community.
Thousands of scientific reports investigated changes in gene, mRNA and protein expression compatible with EMT
and their possible correlation with tumor invasion, metastatic spread or patient prognosis; however, up to now, a
proof of clinical significance of the concept is still missing. This review, with a main focus on the role of EMT in
tumors, will summarize the basic molecular events underlying EMT including the signaling pathways capable of its
induction as well as changes in EMT-associated protein expression and will very briefly touch the role of microRNAs
in EMT. We then outline protein markers that are used most frequently for the assessment of EMT in research and
diagnostic evaluation of tumor specimens and depict the link between EMT, a cancer stem cell (CSC) phenotype
and resistance to conventional antineoplastic therapies. Furthermore, we evaluate a possible correlation between
EMT marker expression and patient prognosis as well as current therapeutic concepts targeting the EMT process
to slow down or prevent metastatic spread of malignant tumors.
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Epithelial-mesenchymal transition (EMT) is a central
element of embryonic development, wound healing and
tumor cell migration, and has thus obtained much atten-
tion by the research community since Greenburg and
Hay firstly described a mesenchymal-like transformation
of epithelial cells when suspended in collagen gels [1].
Basically, the term describes a process in which cells lose
epithelial and gain mesenchymal characteristics; this is
accompanied by a loss of cell-cell cohesiveness, leading
to enhanced migratory capacity [2]. Multiple genes as
well as proteins that seem to play a central role in EMT
have so far been identified and are either up- or down-
regulated during the process, thus serving as possible
markers in the assessment of EMT. Since it seems to be
a key element in wound healing and tumor cell migration,
there is also great interest in EMTas a pharmaceutical tar-
get; recent publications even proposed vaccination against* Correspondence: konrad@steinestel.com
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against tumor progression [3].
However, since many studies on EMT are based on
in vitro results and not all findings could be confirmed
in vivo, the clinical significance of the concept remains
unclear [4]. This review lays the main focus on EMT in
tumor cells and aims at recapitulating what is known
about the molecular basis of EMT. Furthermore, we will
summarize current markers of EMT that are in clinical
and/or diagnostic use and, finally, evaluate EMT from a
translational point of view and in the context of clinical
feasibility.Review
The molecular basis of EMT
Basically, EMT stands for a loss of epithelial and a gain
of mesenchymal cellular characteristics that enhance mi-
gration and invasion by the cell [5]. This process in-
cludes loss of cell cohesiveness as well as fundamental
reorganization of the cytoskeleton inducing a switch
from apical-basal to front-rear polarity, and may further-
more be associated with the acquisition of invasive prop-
erties through the secretion of lytic proteases as well asis an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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under tight control of multiple regulatory pathways; first
and foremost, transforming growth factor β (TGF-β) sig-
naling activity is enhanced in many physiological and
pathological conditions in which EMT is observed, such
as organogenesis, inflammation and tumor invasion [7,8].
In canonical TGF-β signaling, binding of TGF-β to its cell
surface receptors (type I-III) activates complex formation
of Smad family transcription factors, which translocate to
the nucleus and cooperate with transcription factors from
the Snail and Twist family, so-called “EMT master
genes” [9,10]. Non-Smad signaling molecules down-
stream TFG-β and supportive of EMT include activated
Rho-like GTPases, Phosphatidylinositol-3-kinase (PI3K)
and mitogen-associated protein kinase (MAPK; the vari-
ous signaling pathways mediating TGF-β signaling in
EMT are excellently reviewed in [6]). Taken together,
these effectors mediate transcriptional repression of
genes that are involved in cell polarity and cell-cell adhe-
sion, such as RhoA and E-cadherin (Figure 1A) [11,12].
The latter is mediated by the recruitment of histoneFigure 1 Basic molecular changes underlying EMT. A, Signaling along c
(such as Twist, ZEB or Snail) to repress transcription of E-cadherin that initia
Extinction of E-cadherin from the AJ complex as well as concomitant phos
accumulation and nuclear translocation of β-catenin, where it acts as a tran
of Vimentin in migrating tumor cells protects phosphorylated MAPK from c
EGFR/MAPK axis. This supports pro-migratory effects on the cytoskeleton (s
metalloproteinases that cleave the surrounding extracellular matrix to allowdeacetylases (HDACs) and other repressors to E-box ele-
ments in the E-cadherin promoter, leading to chromatin
condensation and transcriptional repression [13]. At the
same time, the expression of N-cadherin, another member
of the cadherin family that allows for enhanced adhesion
between mesenchymal cells, is upregulated; this balanced
change in cadherin expression has thus been designated
“cadherin switch” and is regarded a hallmark of EMT [14].
Not only the expression, but also specific membraneous
targeting of E-cadherin is repressed in EMT via loss of the
epithelial-specific intermediate filament keratin; therefore,
loss of keratin immunostaining is widely regarded as a
marker for ongoing EMT [15,16]. Further mechanisms
that lead to degradation of cell-cell junctions include a
repression of claudin and occludin expression, while
zonula occludens 1 (ZO-1) is subsequently lost in a post-
transcriptional manner [17-19]. This repression is main-
tained throughout further progression of EMT [20]. Since
protein complexes (such as partitioning defective – PAR)
that define the apical compartment of the cell are nor-
mally associated with intercellular junctions, degradationanonical TGF-β pathway activates EMT-promoting transcription factor
lly forms the adherens junction (AJ) complex together with β-catenin.
phorylation via activated growth factor receptors lead to cytoplasmic
scription factor for migration-associated genes. B, Enhanced expression
ytoplasmic phosphatases, thus ensuring signaling activity along the
uch as Rac-mediated actin polymerization) and secretion of lytic matrix
for cell migration.
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cellular phenotype [6]. Moreover, the TGF-β-facilitated
signaling along the MAPK axis exerts pro-proliferative
and anti-apoptotic effects on the cell, while Ras/MAPK
activity alone – without TGF-β induction - has also been
linked to enhanced EMT [21-23]. After losing cohesive-
ness due to degradation of cell-cell junction complexes,
mesenchymal-like tumor cells are able to invade through
the basement membrane into underlying tissue by the se-
cretion of lytic enzymes such as matrix metalloproteinases
(MMPs) and MAPK-mediated reorganization of the actin
cytoskeleton which is enhanced by the expression of
Vimentin (Figure 1B) [24]. In detail, migration and inva-
sion of moving cells is facilitated by specialized cellular
protrusions, such as filopodia, lamellipodia and invadopo-
dia. While filopodia, consisting of actin filaments arranged
in a parallel fashion, seem to sense changes to the cellular
microenvironment and act as a “guide” through the sur-
rounding matrix, lamellipodia are built upon a branched
actin network and allow for actin-myosin interactions as a
prerequisite for cellular movement [25,26]. Both filopodia
and lamellipodia have been linked to an EMT-like pheno-
type in migrating tumor cells [27,28]. Invadopodia are
closely related to lamellipodia in a sense that they also
consist of a branched network of actin filaments, but have
the ability to degrade the extracellular matrix (ECM)
through the secretion of lytic proteases, such as MMP-1,
MMP-7 and MMP-9 (Figure 1B) [26]. Invadopodia forma-
tion has been linked to activity of the EMT transcription
factor Twist1 cancer, and own results showed high expres-
sion of invadopodia-associated proteins, such as Cortactin
and Abelson interactor 1 (Abi1), in a colorectal carcinoma
cell line with an EMT-like phenotype shown by loss of
E-cadherin [29,30]. Accordingly, TGF-β signaling activates
small GTPases that enhance local reorganization of the
actin cytoskeleton as a prerequisite for lamellipodia and
filopodia formation, such as Rho, Rac and Cdc42 [31].
Vimentin, which is frequently upregulated in cells with an
EMT-like phenotype, is then required for the further
maturation of invadopodia [32]. Besides clearing the way
for migrating tumor cells, MMPs that are released during
tumor cell invasion are themselves further fueling the
EMT process; the same effect is achieved via liberated
TGF-β from the ECM [33-35]. In a mouse model of gas-
tric cancer, it could be shown that EMT cooperates with
MMP activity to gain access to lymph vessels and to
spread distant metastases [36]. Accordingly, blood and
lymph vessel infiltration by triple-negative breast cancer
cells is associated with the expression of EMT transcrip-
tion factor Zeb1 in surrounding stroma [37]. Alterations
in MMP expression are linked to changes in the integrin
repertoire with downregulation of some (epithelial) and
upregulation of other integrins that facilitate interaction
with extracellular matrix components such as collagen [6].Targeting transmembrane proteins - like E-cadherin - or
increasing the levels of intracellular reactive oxygen spe-
cies via enhanced activation of Rac1b are further mecha-
nisms of MMP-induced EMT [38,39].
Upon arrival at the site of metastasis, it seems a pre-
requisite for metastatic colonization that tumor cells
undergo a partial reversal of the EMT, the so-called
“mesenchymal-epithelial transition” (MET) [40,41]. Dur-
ing that process, tumor cells regain the expression of epi-
thelial markers, such as E-cadherin, while the expression
of EMT-associated transcription factors, such as Twist1, is
repressed [41]. Thus, EMT can be seen as a reversible and
transient process that enables epithelial tumor cells to gain
access to the vasculature, allowing for the formation of
distant metastasis.
Besides TGF-β, other signaling pathways have also
been implied in the activation of EMT; for example,
hypoxia-inducible factor (HIF) contributes to EMT in
tissue fibrosis and cancer cell invasion by modulating
the activity of pro-EMT transcription factors Notch and
β-catenin [42-44]. HIF1α induces Twist and Snail ex-
pression in endothelial as well as ovarian carcinoma cells
[45-47]. Additionally, activation of several receptor tyro-
sine kinases (RTKs) may result in induction of EMT; in
these scenarios, growth factor binding to RTKs as well
as activating mutations in oncogenes downstream of the
receptors leads to enhanced signaling along the Ras/
MAPK or Akt/mTOR axis, resulting in upregulation of
Snail expression [6]. Finally, it has been shown that en-
hanced wnt signaling activity as well as an upregulation
of chemokine receptors (such as CXCR-1) also support
the process of EMT [48,49]. Here, wnt signaling leads to
an inhibition of glycogen synthase kinase 3β (GSK3β)-
mediated phosphorylation of β-catenin; the resulting
decrease in proteosomal degradation and cytoplasmic
accumulation of β-catenin supports its translocation to
the nucleus, where it acts as a transcriptional co-activator
of EMT-associated gene expression [50].
In the recent years, the role of small, non-coding
RNAs in the EMT process has also been further eluci-
dated. Methylation-depedent expression changes in
levels of miR-200c and miR-141, for example, regulate
invasion and metastasis in colorectal cancer via altered
miR-200c target gene expression; miR-375 is downregu-
lated in tamoxifen-resistant breast cancer cells with
EMT-like properties, and its reexpression partly reverses
EMT [51,52]. Other miRNAs that have been discussed
to play a central role in EMT are, among others, miR-1,
9, 24, 29b, 30a, 31, 124, 155, 192/215 and 661 (reviewed
in [6]). Their mechanisms of action include post-
transcriptional regulation of “EMT master genes” or of
genes defining the epithelial or mesenchymal phenotype
of the cell (such as E-/N-cadherin or vimentin). How-
ever, a thorough review of the role of miRNAs in EMT
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scope of this text, where we would like focus on the role
of well-characterized proteins in EMT.
Tissue markers of EMT
Unlike the various mechanisms that are known to initiate
or repress EMT, the observed hallmarks of established or
ongoing EMT are quite consistent. As previously men-
tioned, loss or degradation of proteins associated with epi-
thelial homeostasis, cell polarity and cell adhesion, such as
E-cadherin, RhoA or Plakophilin 2 is frequently observed
in EMT (Figure 1A); some proteins that play key roles in
cell-cell adhesion when attached to the membrane, such
as β-catenin, are redistributed to the cytoplasm [11,12,17].
Moreover, cells undergoing EMT show decreased expres-
sion of epithelial cytokeratin filaments, such as keratins 8
and 18 [53]. On the other hand, the intermediate filament
protein Vimentin is frequently overexpressed and contrib-
utes to cell migration as well as invasion-associated gene
expression by stabilizing the phosphorylated state of
MAPK and is thus regarded as a stable marker of EMT;
moreover, its presence is a prerequisite for the maturation
of invadopodia which are indispensable for cell invasion
[32,54,55]. Dysregulated expression of transcription fac-
tors, such as Notch1, Slug, Snail, Twist or Zeb1 has been
described in invasive tumors displaying EMT; theseTable 1 Frequently used protein markers for epithelial-mesen
Marker Original function Tis
Downregulated in EMT
α-catenin Cell adhesion molecule Lu
β-catenin (membrane)1 Cell adhesion molecule Co
Claudin Cell adhesion molecule Eso
Cytokeratins Cytoskeletal filament Lu
E-cadherin Cell adhesion molecule Co
Occludin Cell adhesion molecule Ov
Upregulated in EMT
Brachyury Transcription factor Pa
β-catenin (cytoplasm/ nucleus)1 Transcription factor Bre
EGFR Tyrosine kinase receptor Ce
N-cadherin Cell adhesion molecule Ov
Notch-1 Transcription factor Pro
p16INK4a Cell cycle regulator Co
Slug Transcription factor Bre
Snail Transcription factor Bre
TTF-1 Transcription factor Lu
Twist Transcription factor Bre
Vimentin Cytoskeletal filament Bre
ZEB1 Transcription factor Co
1Membraneous depletion, but cytoplasmic accumulation/nuclear translocation.
NET, neuroendocrine tumor; EGFR, epidermal growth factor receptor; TTF-1, thyroid tramarkers are therefore designated as “EMT master genes”.
Table 1 provides an overview over selected dysregulated
protein markers that have been and still are frequently
used in the assessment of EMT.
EMT, tumor invasion and metastasis
The highest clinical significance of the EMT process is
linked to its role in tumor cell invasion and metastasis.
In a transgenic mouse model of pancreatic beta-cell car-
cinogenesis, the switch from noninvasive adenoma to in-
vasive carcinoma is associated with a loss of E-cadherin
expression [82]; moreover, it has been shown that loss of
membraneous β-catenin is associated with tumor cell
budding, a morphologic hallmark of invasive tumor
phenotype and tumor aggressivity in colorectal cancer
tissue specimens [83-85]. In samples from 49 breast can-
cer patients, the single-cell infiltration pattern that is ob-
served in some lobular carcinomas has been linked to
protein truncation mutations in the CDH1 gene encod-
ing for E-cadherin [86], and hypoxia-induced upregula-
tion of Slug and Snail is associated with increased breast
cancer cell migration and invasion in vitro [77]. Accord-
ingly, expression of Vimentin can be found in many ag-
gressive breast cancer cell lines [87]. As mentioned above,
to allow for tumor cell invasion into the vasculature as a
prerequisite for metastatic seeding, EMT cooperates withchymal transition (EMT)
sue Reference
ng [56]
lon, Pancreas (NET) [57,58]
phagus, Breast [59,60]
ng, Esophagus [16,61,62]
lon, Breast, Lung, Ovary, Esophagus, Prostate, Cervix [16,61,63-70]
ary [18,71]







ast, Cervix, Ovary [11,70,77]
ng [61]
ast, Stomach [78,79]
ast, Esophagus, Cervix [16,55,62,70]
lon, Breast, Ovary [51,68,80,81]
nscription factor-1; ZEB1, Zinc finger E-box-binding homeobox 1.
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ing tumor cells (CTCs) obtained from peripheral blood of
breast cancer patients frequently show an EMT-like
phenotype [88,89]. In human and murine malignant mel-
anoma cells, metastatic dissemination is enhanced and ac-
celerated via Snail-induced EMT [90], and bone
metastases of human prostate carcinomas show significant
overexpression of Notch-1 compared to the primary tu-
mors [75]. In lung carcinoma surgical specimens, tumor
dedifferentiation as well as lymphogenous metastasis are
also associated with reduced E-cadherin expression [91].
However, as mentioned above, some authors also
reported reexpression of epithelial markers, such as
E-cadherin, along with loss of EMT-associated tran-
scription factors in established metastases [41]. This
apparent reversal of EMT, often referred to as mesenchymal-
epithelial transition (MET), has been described for
metastases of colorectal carcinoma, non-small cell lung
cancer and transitional cell carcinoma [92-94]. There is
an ongoing debate regarding the extent to which these
findings reflect a basic mechanism in the establishment
of metastases or if they are restricted to certain tumor
entities or reflect distinct circumjacent conditions [4,41].
There are also critical voices that doubt the role of EMT
in invasion at all, since in most histopathologic speci-
mens, many tumors invade and metastasize by cohesive
and multicellular rather than single-cell migration, and
histopathologists rarely see abundant mesenchymal-like
tumor cells in routine surgical specimens [4,95,96]. This
apparent contradiction might in part be explained by re-
garding EMT as a transient state of a small proportion
of migrating tumor cells, with only single tumor cells
or small clusters of cells obtaining the ideal dynamic
configuration for different stages of invasion and me-
tastasis; this reasonable compromise has been referred
to as “spatial and temporal heterogeneity of EMT” by
Voulgari et al. (Figure 1) [97,98].
Notably, there is another controversy regarding the
point whether the EMT program is associated with en-
hanced or attenuated proliferative activity of the cell.
While under normal circumstances TGF-β signaling ex-
erts an anti-proliferative and pro-apoptotic effect, there
is experimental evidence that tumor cells having under-
gone EMT do in fact show enhanced proliferation and
resistance to apoptosis [99,100]. This apparent contradic-
tion might also be explained by a possible heterogeneity in
the course and the extent of EMT, with specialized cell
populations exerting different roles during invasion and
metastasis; this is in line with findings that highly meta-
static breast cancer cells in fact show strong activity of the
TGF-β signaling pathway [101]. It has also been proposed
that the two oppositional endpoints of TGF-β signaling
might be distinguished by loss of Smad4 in tumor tissue,
which promotes TGF-β-mediated tumorigenesis, while inparallel abolishing its tumor-suppressive functions [102].
Additionally, as described above, signaling along various
non-TGF-β-dependent pathways might be capable of
overcoming the original anti-tumorigenic effect of TGF-β
in the course of an “unfriendly takeover” of central TGF-β
signaling nodes and target genes; concurrent PI3K/AKT
signaling, for example, thwarts the pro-apoptotic effect of
TGF-β, thus selectively allowing for the pro-metastatic ef-
fects of the pathway to occur [13,49,50,77].
EMT, cancer stem cells and therapy resistance
Concerning the role of EMT in antitumoral therapies, it
has been shown that an EMT-like cellular phenotype in
both surgical specimens and cell lines is associated with
increased resistance to most conventional approaches,
such as chemotherapy [103-105], radiotherapy [106] or
hormone withdrawal [107,108]. The observed changes in
gene expression during EMT show striking similarity to
a rather dedifferentiated state of the cell; in immortal-
ized mammary epithelial cells, induction of EMT not
only leads to the gain of a mesenchymal phenotype, but
also induces the expression of certain stem cell markers
(CD44+/CD24−) [109]. This generation of breast cancer
cells with both cancer stem cell and mesenchymal-like
characteristics has again been shown to be dependent on
an activation Ras/MAPK signaling, and the link between
EMT and cancer cell “stemness” is supported by the fact
that genes associated with angiogenesis, invasion and me-
tastasis are overexpressed in stem cell- like CD44+/CD24−
breast cancer cells; notably, after chemotherapy for breast
cancer, residual tumor cells frequently display a stem cell-
like phenotype and increased mammosphere formation ef-
ficiency [101,110,111]. The sensitivity of non-small cell
lung cancer cells to EGFR kinase inhibition depends on
their respective EMT phenotype, with mesenchymal-like
cells (that express Vimentin or Fibronectin) being less sen-
sitive to EGFR inhibition [112]. In the NSCLC model, it
has also been shown that this resistance might be medi-
ated via EGFR-independent MEK-Erk pathway activation
and PDGFR, FGFR and TGF-β receptor acquisition in
mesenchymal-like tumor cells [113]. An EMT-like gene
expression profile in lung cancer cell lines is in fact associ-
ated with increased resistance to both EGFR and PI3K/
Akt pathway inhibitors, a finding that could even be con-
firmed in a small patient cohort [114]. Thus, the mecha-
nisms of resistance to antineoplastic therapies might be
due to stem-cell like properties of tumor cells that have
undergone EMT, allowing for self-renewing of a propor-
tion of cells within the tumor based on the activation of
central signaling pathways that are common to both pro-
cesses, such as TGF-β, wnt, Notch and Hedgehog [13].
Associations between EMT-like properties and a stem-cell
like cellular phenotype have not only been described in
carcinoma of the breast and in NSCLC, but also in
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carcinoma; here, increased resistance to anti-epithelial
growth factor receptor (EGFR)-directed therapy is also
associated with an EMT-like phenotype of the tumor
cells [115].
EMT and patient prognosis
Since the metastatic spread of malignant tumors accounts
for the majority of cancer-specific deaths [116-118], pos-
sible correlations between EMT markers and patient
prognosis have been intensely studied in multiple tumor
entities. However, there is still controversy regarding the
impact of the EMT concept on the actual situation in hu-
man malignancies [119]. Therefore, much effort has been
put into linking the expression of EMT markers to data
on patient survival. In colon cancer, the upregulation of
genes involved in EMT/matrix remodeling defines a mo-
lecularly distinct subtype with very unfavorable prognosis;
downregulation of E-cadherin in patient samples, on the
other hand, seems to be associated with high TNM stages
and distant metastasis [120,121]. Accordingly, basal-like,
triple-negative breast cancers that show upregulation of
Vimentin have a poor prognosis [54,87]. In a meta-
analysis of 1107 breast cancer samples, Tobin et al.
showed reduced recurrence free survival in tumors dis-
playing increased gene expression of EMT markers
SNAI2, TWIST1 and VIM, and decreased levels of
CDH1 (encoding for E-cadherin) [122]. In contrast, only
recently Lee et al. were unable to confirm an impact of
the tissue expression of EMT markers on disease-free
survival or overall survival in breast cancer patients
[123]. In prostate cancer, expression levels of EMT
markers Twist and Vimentin - as assessed by immuno-
histochemistry in radical prostatectomy specimens - are
independent predictors for biochemical recurrence as
defined by a resurgence in serum prostate-specific anti-
gen (PSA) levels following surgery [124]. Additionally,
loss of membraneous E-cadherin staining seems to be
associated with increased Gleason score, advanced clin-
ical stage, and poor prognosis in prostate cancer [125].
In tissue samples from 354 primary tumors and 30 metas-
tases of endometrial carcinomas, Tanaka et al. reported
that EMT status (E-cadherin-negative/ Snail-positive im-
munostaining) correlated with histological type, FIGO
stage, myometrial invasion and positive peritoneal
cytology while it was inversely associated with both
progression-free survival (HR = 0.443) and overall sur-
vival (HR = 0.366) [126].
Taken together, numerous studies in a variety of tumor
entities show statistical correlations between patient
prognosis and alterations of various markers compatible
with EMT. However, it may be difficult to yield reliable
prognostic information for an individual patient from
the expression pattern of EMT markers in surgicalspecimens; this is in part due to high variability of
marker expression patterns in different tumor areas in a
heterogeneous sample [127,128]. Moreover, artificial in-
duction of EMT in vitro (under certain cell culture
conditions) as well as in vivo (in surgical specimens sub-
jected to ischemia) has been shown [129,130]. Another key
problem is the lack of a standardized diagnostic definition
of which gene or which extent of expression changes is suf-
ficient to determine EMT; in many reports, expression
changes of one or two genes are already referred to as
EMT or “partial EMT”, thus impairing the comparability
of studies [4,131]. Furthermore, as has already been dis-
cussed above, it is still unclear whether the gene expression
changes observed in EMT reflect “passenger mutations”
caused by genetic instability during tumor dedifferentiation
rather than a real mesenchymal transdifferentiation state of
the cell [4]. From this point of view, the expression of
EMT markers simply represents a more primitive differen-
tiation state of the cancer cell that is associated with onco-
genic activation of a variety of signaling molecules [132].EMT as a potential target for antineoplastic therapies
Since the population of stem cell-like tumor cells will
always bear considerable resistance to conventional ther-
apies and since the hallmarks of EMT have been identified
in a significant proportion of these cells as described
above, efforts have been made to develop antineoplastic
therapies that directly target EMT. The aim of most thera-
peutic approaches is to block or slow down invasion and
metastasis in tumors or, in benign conditions associated
with EMT, impede fibrotic organ remodeling [96,133].
Table 2 shows some current therapeutic approaches that
are aiming at EMT, most of them targeting kinase signal-
ing pathways upstream EMT master gene expression. In
mouse hepatocytes that have undergone EMT, it has been
shown that inhibition of STAT3 signaling, for example, re-
duces EMT-like changes; in renal tubular epithelium, ALK
receptor activation via recombinant BMP-7 acts antagon-
istically to TGF-β and leads to reexpression of E-cadherin
[134-136]. Inhibition of kinase signaling downstream
FGFR3, ILK, Ras/MAPK or PI3K/AKT downregulates
tumor formation, EMT master gene expression and inva-
sive potential in colorectal, lung and pancreatic carcinoma
cells in vitro, while in some models, re-expression of
E-cadherin could be shown upon treatment with kinase
inhibitors [137-140]. In a mouse model of hepatocellu-
lar carcinoma, transformation with kinase-inactivated
integrin-linked kinase (KI-ILK) partially restored the
sensitivity to anti-EGFR treatment [141]. Accordingly,
our own group showed that Ras-driven EMT is attenu-
ated via Sorafenib-mediated inhibition of Urokinase
plasminogen activator (uPA) expression in RT112 urothe-
lial carcinoma cells [23].
Table 2 Therapeutic approaches targeting EMT in benign and malignant processes
Organ/entity Target Approach Mechanism Effect Ref.
Liver
(Hepatocytes)
STAT3 Sorafenib Inhibition of STAT3
phosphorylation









E-cadherin ↑ [111, [136]
Colorectal cancer FGFR4 siRNA
Knockdown
Reduction of Src and
MEK1/2-ERK1/2 signaling









Reduction of Akt signaling Sensitivity to anti-EGFR therapy ↑ [141]
Lung
adenocarcinoma




HDAC expression↓, possibly via





T-cell mediated cytotoxicity Lysis of Brachyury-positive
tumor cells
[3]
Axl RTK SGI-7079 Inhibition of Axl phosphorylation Growth of mesenchymal
NSCLC xenograft tumors ↓
[114]
Breast cancer LYN kinase Dasatinib Inhibition of LYN kinase activity Invasion ↓ [142]
EMT master gene
expression










Sorafenib Inhibition of Ras/MAPK signaling uPA ↓, [23]
E-cadherin ↑





















STAT3, Signal transducer and activator of transcription 3; TGF-β, transforming growth factor β; ALK3, activin-like kinase 3; BMP-7, bone morphogenetic protein 7, FGFR4,
fibroblast growth factor receptor 4; Src, sarcoma kinase; MEK, mitogen-associated protein kinase kinase; ERK, extracellular signal-related kinase; siRNA, small interfering
RNA; ILK, integrin-linked kinase; AKT, protein kinase B; HAT, histone acetyltransferase; HDAC, histone deacetylase; EGFR, epidermal growth factor receptor; RTK, receptor
tyrosine kinase; NSCLC, non-small cell lung cancer; LYN, Lck/Yes-related novel protein tyrosine kinase; MMP, matrix metalloproteinase; uPA, urokinase plasminogen
activator; ZEB1, Zinc finger E-box-binding homeobox 1; PI3K, phosphatidylinositol-3-kinase.
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signaling pathways that are activated during EMT, it is not
surprising that the application of multi-kinase inhibitors
such as Sorafenib is capable of reversing the process to a
certain extent. Up to now, concepts that are directly tar-
geting EMT master genes or their effectors are rare. Inter-
esting new approaches include the previously mentioned
vaccination against Brachyury-positive tumor cells and the
transcriptional repression of EMT master gene expression
by the anti-diabetic drug Metformin (Table 2) [3,72,143].
Resveratol, a dietary polyphenol, downregulated expres-
sion of EMT master genes Zeb1, Snail and Slug and im-
paired CSC self-renewal capacity, tumor growth and
invasion in a mouse model of pancreatic ductal adenocar-
cinoma [144]. However, despite the abundance of litera-
ture on effectors of EMT, there is a lack of studies that
show a solid effect of a specific compound in an in vivo
system additionally to cell culture data, and to our best
knowledge, a study that rescued the EMT phenotype after
application of a certain compound - for example by over-
expressing an EMT-inducing transcription factor - has
so far not been conducted. Therefore, most of the data
on drugs targeting EMT has to be regarded as prelimin-
ary, and further research is needed to identify valuable
pharmacologic targets during the induction or progres-
sion of the EMT process.
Conclusions
Taken together, the concept of EMT is a valuable model
for the morphologic and molecular changes observed in
tumor cell invasion as well as tissue fibrosis. However, it
is still unclear whether or to which extent cells in fact
do undergo a complete conversion of cell type or show
only transient changes in cellular morphology and pro-
tein expression patterns that are supportive of a migra-
tory phenotype. Despite the controversies dealing with
the definition and extent of EMT, the association be-
tween an EMT-like cellular phenotype - as shown by
changes in marker protein expression - and tumor ag-
gressivity has been well-proven in a variety of malignan-
cies. In recent years, first promising results have been
reported concerning a possible use of the EMT process
as a pharmacological target, especially with multi-kinase
inhibitors such as Sorafenib. However, since most of
these results are actually derived from in vitro data and
definite proof of druggable EMT in vivo is still missing,
the clinical utility of these approaches remains to be elu-
cidated in future studies.
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